Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Document Type
Journal Article
Publication Date
6-1-2020
Journal
Obstetrics and Gynecology
Volume
135
Issue
6
Inclusive Pages
1313-1326
DOI
10.1097/AOG.0000000000003869
Keywords
Adult; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estradiol; Female; Gonadotropin-Releasing Hormone; Headache; Hot Flashes; Humans; Hydrocarbons, Fluorinated; Leiomyoma; Menorrhagia; Middle Aged; Nausea; Norethindrone; Pyrimidines; Quality of Life; Uterine Neoplasms
APA Citation
Simon, J. A., Al-Hendy, A., Archer, D., Barnhart, K., Bradley, L., Carr, B., Dayspring, T., Feinberg, E., Gillispie, V., Hurtado, S., Kim, J., Liu, R., Owens, C., Muneyyirci-Delale, O., Wang, A., Watts, N., & Schlaff, W. (2020). Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.. Obstetrics and Gynecology, 135 (6). http://dx.doi.org/10.1097/AOG.0000000000003869
